Open access · US-GOV
via ClinicalTrials.gov Clinical trial
[18F]-T807 PET/CT Imaging of Tau Pathology in Young Onset Focal Dementia
Authors not listed
University of Pennsylvania · 2014
Abstract
The central goal of this study is to determine and compare the similarities and differences in regional brain uptake of \[18F\]T807 in patients with typical Alzheimer's Disease (AD), Posterior Cortical Atrophy (PCA), and Logopenic Variant of Primary Progressive Aphasia (lvPPA). The investigators will correlate patterns of \[18F\]T807 binding with magnetic resonance imaging (MRI)-based regional volumetric and cortical thickness measures. If cerebral spinal fluid (CSF) samples are not available, patients may be asked to get an optional lumbar puncture (LP) for additional comparisons. The investigators will recruit 20 participants, 45-70 years old, with clinical evidence of young onset focal dementia.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-08 MST
Cite this
APA
Anonymous. (2014). [18F]-T807 PET/CT Imaging of Tau Pathology in Young Onset Focal Dementia. <em>University of Pennsylvania</em>. https://clinicaltrials.gov/study/NCT02289118
Vancouver
Anonymous. [18F]-T807 PET/CT Imaging of Tau Pathology in Young Onset Focal Dementia. University of Pennsylvania. 2014.
BibTeX
@misc{anon2014FTPETC,
title = {[18F]-T807 PET/CT Imaging of Tau Pathology in Young Onset Focal Dementia},
author = {Anonymous},
journal = {University of Pennsylvania},
year = {2014},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
University Hospital, Toulouse 2018
Open access · US-GOV
Effect of Neflamapimod (VX-745) on Brain Inflammation Using Positron Emission Tomography (PET) Scan in Alzheimer's Disease (AD) Patients
Johns Hopkins University 2020
Open access · US-GOV
Comparison of [18F]RO-948, [18F]MK-6240, and [18F]AV-1451 TAU Radiopharmaceuticals in Patients With Alzheimer's Disease and Older Controls
University of Pennsylvania 2022
Open access · US-GOV
Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Disease Using the PET Ligand [18F]-PI-2620
Aleksandra Stark 2017
Open access · US-GOV
A Phase IIa Proof of Concept, Randomized, Double-blind, Placebo-controlled Study of the Effects of L-serine on Early Stage Alzheimer's Disease Patients
Sinotau Pharmaceutical Group 2021
Open access · US-GOV
Single-arm, Single-center, Non-randomized, Open-label Study on the Application of Amyloid Imaging Agent [18F]Florbetaben(18FBB) PET/CT Imaging to Distinguish Non-cognitively Impaired Subjects and Mild to Moderate Alzheimer Disease Subjects in Chinese Population
Chang Gung Memorial Hospital 2021
Open access · US-GOV